GE Healthcare Life Sciences announced today that it will license Cellular Dynamics International (CDI) to develop, manufacture and sell cellular assays and models derived from induced pluripotent stem cells for use in drug discovery and toxicity screening.

“We believe it is important that stem cell-based assays are available to researchers so that progress can be made in drug discovery,” Dr. Amr Abid, general manager of cell technologies at GE Healthcare, said in a statement. “We are delighted that Cellular Dynamics International is the first company to work with us to bring greater clarity to the marketplace.”

CDI also features a custom cell manufacturing service that leverages the ability of iPS cell technology to make stem cells or terminal cells from any individual. Dr. James Thomson of the University of Wisconsin founded the company in 2004.

Financial terms of the deal were not disclosed.